<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007526</url>
  </required_header>
  <id_info>
    <org_study_id>2008-04-033</org_study_id>
    <nct_id>NCT01007526</nct_id>
  </id_info>
  <brief_title>Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma</brief_title>
  <acronym>CCRT-VIDL</acronym>
  <official_title>Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy of risk-adapted treatment strategy for stage I/II
      extranodal NK/T cell lymphoma. The risk stratification is based on the Korean NK prognostic
      index. Thus, the group I/II will receive concomitant chemoradiation followed by VIDL
      chemotherapy. The group III/IV will receive high dose-chemotherapy followed by autologous
      stem cell transplantation after the completion of VIDL chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Concomitant chemo-radiotherapy:

           Radiotherapy 36-44 Gy/18-22 fractions

           + weekly cisplatin 30 mg/m2 for 4 weeks

        2. Rest period: 3 weeks

        3. VIDL combination chemotherapy: (total 2 cycles) VP-16 (etoposide) 100mg/m2 I.V. D1-3
           Ifosfamide 1.2g/m2 I.V. D1-3 Dexamethasone 40mg/day D1-3 L-asparaginase 4000IU/m2 IM D8,
           10, 12, 14, 16, 18, 20 Repeated every 28 days

        4. Peripheral blood stem cell mobilization G-CSF 400ug/m2/day or 10ug/kg/day S.C. or I.V.
           for 4-6 days followed by stem cell collection (Minimum requirement of CD34+ cells &gt;
           2Ã—106/kg)

        5. High-dose chemotherapy with autologous stem cell transplantation Busulfex 3.2mg/kg/day
           from day -7 to day -5 Etoposide 400mg/m2/day on day -5, -4 Cyclophosphamide 50mg/kg/day
           on day -3, -2 Followed by stem cell infusion
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compete response rate</measure>
    <time_frame>Within 3 weeks after the completion fo treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, survival, toxicity</measure>
    <time_frame>Up to 5 years after the completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stage I/II Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation</intervention_name>
    <description>concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients were required to have a biopsy-proven diagnosis of nasal ENKTL

          -  at least 18 years old

          -  Ann Arbor stage IE or IIE

          -  measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  life expectancy greater than 12 weeks

          -  adequate hematologic (hemoglobin &gt; 9.0 g/dL, absolute neutrophil count &gt; 1,500/uL and
             platelets &gt; 100,000/uL)

          -  renal (serum creatinine &lt; 1.5 mg/dL, creatinine clearance &gt; 50 mL/min)

          -  hepatic (total bilirubin &lt; 2 times of upper limit of normal and aspartate transferase
             &lt; 3 times of upper limit of normal) function

          -  Diagnosis of ENKTL is based on the presence of histological features and
             immunophenotypes compatible with ENKTL (e.g., cytoplasmic CD3+, CD20-, CD56+, positive
             for cytotoxic molecules, positive for EBV by in situ hybridization).

          -  Informed consent

        Exclusion Criteria:

          -  prior or concomitant malignant tumors

          -  any coexisting medical problems of sufficient severity to prevent full compliance with
             the study protocol.

          -  ENKTL with non-nasal sites such as skin or gastrointestinal tract was excluded even if
             it is localized.

          -  Other subtypes of non-Hodgkin lymphoma (NHL), including myeloid/NK cell precursor
             acute leukemia, blastic NK cell lymphoma/precursor NK cell lymphoblastic leukemia,
             aggressive NK cell leukemia, and peripheral T cell lymphoma, unspecified, were
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Seog Kim, MD, PhD</last_name>
    <phone>82234106548</phone>
    <email>wskimsmc@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Won Seog Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Extranodal Lymphoma</keyword>
  <keyword>Natural killer cell</keyword>
  <keyword>T cell</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 30, 2012</submitted>
    <returned>February 1, 2013</returned>
    <submitted>February 10, 2013</submitted>
    <returned>March 13, 2013</returned>
    <submitted>June 3, 2013</submitted>
    <returned>July 9, 2013</returned>
    <submitted>October 25, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

